News

Stem Cell Sciences’s (SCS’s) IRES (internal ribosome entry site) technology enables researchers to monitor the activity of a gene of interest in living cells or tissues without blocking

The two studies, known as Lume-Lung 1 and Lume-Lung 2, for Vargatef, a triple angiokinase inhibitor, will evaluate the molecule as a second-line therapy in combination with standard

The mandate of PharMida is to develop a strong portfolio of clinically validated gold nanoparticle-drug combinations. Furthermore, PharMida will have the responsibility to project manage in-house drug development,

According to Nanosonics’s director and CEO David Radford, this represents the achievement of another key milestone in the commercialization of the company’s launch product, the Trophon EPR, scheduled

The net loss for the nine-month period ended September 30, 2008 was $12.4 million, or $(0.71) per basic and diluted share, as compared to a net loss of

As part of its effort to restructure and consolidate operations, Neurogen has entered into a purchase and sale agreement to sell four of its five buildings for a

Shreya will offer the product through its sales force of more than 1,000 people and will implement a continuing medical education program to introduce the product to endocrinologists,

The Phase III clinical trial for adults is designed to test the efficacy and safety of CS-8958 in several hundred adult patients per group who have confirmed, naturally

From May 2007 until September 2008, Mr Garland was CEO of Acambis, a company engaged in the development of novel vaccines. During this period he oversaw a series